ArriVent BioPharma, Inc. (AVBP) vs Starling Oncology, Inc. (STLN)

A side-by-side comparison of ArriVent BioPharma, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
ArriVent BioPharma, Inc. logo
AVBP
ArriVent BioPharma, Inc.
$703M
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Starling Oncology, Inc. logo
STLN
Starling Oncology, Inc.
$658M
$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AVBP vs STLN

growth of $100 · dividends reinvested · last 1y
AVBP -16.7% (-16.7%/yr)STLN +8.6% (+8.6%/yr)STLN compounded faster over this window
8090100110120Start $100$83$109
AVBP STLN

AVBP vs STLN: by the numbers

  • •AVBP is the larger company ($703M vs $658M market cap).
  • •Both run net losses; AVBP's is the smaller (0.00% vs -6.18% net margin).

Metrics side by side

Valuation

MetricAVBPSTLN
P/S ratioN/A1.12
P/B ratio1.92N/A

Profitability

MetricAVBPSTLN
Gross margin0.00%15.69%
Operating margin0.00%-4.44%
Net margin0.00%-6.18%
ROE-44.63%N/A
ROIC-47.96%-31.32%

Go deeper

Full AVBP analysisFull STLN analysisInteractive comparison tool

Dig into the metrics

ArriVent BioPharma ROEStarling Oncology ROEArriVent BioPharma operating marginStarling Oncology operating marginArriVent BioPharma revenue growthStarling Oncology revenue growthArriVent BioPharma free cash flowStarling Oncology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.